CONMED Corporation (CNMD) Analysts See $0.42 EPS

July 17, 2017 - By Clifton Ray

 CONMED Corporation (CNMD) Analysts See $0.42 EPS
Investors sentiment increased to 0.97 in Q4 2016. Its up 0.12, from 0.85 in 2016Q3. It increased, as 12 investors sold CONMED Corporation shares while 48 reduced holdings. 17 funds opened positions while 41 raised stakes. 26.92 million shares or 2.31% less from 27.56 million shares in 2016Q3 were reported.
Cramer Rosenthal Mcglynn Lc holds 0.67% or 1.02 million shares in its portfolio. Champlain Inv Ltd Liability Corporation has 1.48 million shares. Texas Permanent School Fund accumulated 18,061 shares. Ls Advsr Ltd Co invested in 1,039 shares. D E Shaw & owns 40,033 shares for 0% of their portfolio. Tower Research Ltd Liability Corp (Trc) reported 0% of its portfolio in CONMED Corporation (NASDAQ:CNMD). Massachusetts Communication Ma accumulated 46,794 shares or 0% of the stock. Parkside State Bank And Trust owns 15 shares. California State Teachers Retirement Sys holds 56,838 shares. State Street has 630,996 shares. Putnam Invs Ltd holds 26,453 shares or 0% of its portfolio. Camber Capital Ltd Limited Liability Company accumulated 750,000 shares. Voya Management Ltd Liability Corp has 0% invested in CONMED Corporation (NASDAQ:CNMD). Bnp Paribas Arbitrage Sa invested in 7,352 shares or 0% of the stock. 12,901 are held by Aqr Capital Mngmt Ltd Limited Liability Company.

Since March 6, 2017, it had 4 buys, and 2 selling transactions for $347,557 activity. The insider Farkas Charles bought $7,994. Another trade for 1,000 shares valued at $52,239 was sold by Kuyper Dirk. On Monday, March 6 the insider TRYNISKI MARK E bought $205,750. Cohen Heather L bought $17,598 worth of stock or 440 shares. 8,030 CONMED Corporation (NASDAQ:CNMD) shares with value of $322,115 were bought by Hartman Curt R.

Wall Street await CONMED Corporation (NASDAQ:CNMD) to release earnings on July, 26. Analysts forecast earnings per share of $0.42, down exactly $0.05 or 10.64 % from 2014’s $0.47 EPS. The expected CNMD’s profit could reach $11.73M giving the stock 30.27 P/E in the case that $0.42 earnings per share is reported. After posting $0.38 EPS for the previous quarter, CONMED Corporation’s analysts now forecast 10.53 % EPS growth. The stock increased 0.20% or $0.1 during the last trading session, reaching $50.85. About 75,914 shares traded. CONMED Corporation (NASDAQ:CNMD) has risen 27.59% since July 18, 2016 and is uptrending. It has outperformed by 10.89% the S&P500.

CONMED Corporation (NASDAQ:CNMD) Ratings Coverage

Among 4 analysts covering CONMED Corporation (NASDAQ:CNMD), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. CONMED Corporation had 9 analyst reports since July 22, 2015 according to SRatingsIntel. The stock has “Buy” rating by Ladenburg Thalmann on Monday, October 12. Northland Capital downgraded CONMED Corporation (NASDAQ:CNMD) on Wednesday, July 22 to “Market Perform” rating. Piper Jaffray maintained CONMED Corporation (NASDAQ:CNMD) rating on Thursday, August 27. Piper Jaffray has “Neutral” rating and $51 target. The stock of CONMED Corporation (NASDAQ:CNMD) has “Buy” rating given on Friday, November 18 by Needham. The firm earned “Outperform” rating on Monday, October 5 by Leerink Swann. The company was maintained on Thursday, April 28 by Needham. The stock of CONMED Corporation (NASDAQ:CNMD) earned “Market Perform” rating by Northland Capital on Thursday, October 22.

CONMED Corporation is a medical technology company. The company has market cap of $1.42 billion. The Firm is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. It has a 115.03 P/E ratio. The Firm provides surgical devices and equipment for minimally invasive procedures.

More recent CONMED Corporation (NASDAQ:CNMD) news were published by: Businesswire.com which released: “CONMED Corporation to Announce Second Quarter 2017 Financial Results on July …” on July 10, 2017. Also Prnewswire.com published the news titled: “MedShape Sells ExoShape┬« ACL Product Line to CONMED Corporation” on July 05, 2017. Reuters.com‘s news article titled: “BRIEF-MedShape sells ExoShape ACL product line to CONMED Corp” with publication date: July 05, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.